CYP1A1 and CYP1B1 are the primary enzymes governing estrogen hydroxylation — determining the ratio of 2-hydroxyestrone (protective) to 4-hydroxyestrone and 16α-hydroxyestrone (proliferative). Variants that shift this balance toward 4- and 16-pathway metabolites increase DNA-damaging quinone formation — a key mechanism in hormone-related cancer risk and endometrial health.
COMT methylates catechol estrogens for clearance. Low-activity COMT variants (Met/Met) reduce the rate of estrogen detoxification — elevating exposure to reactive estrogen metabolites. The combination of CYP1B1 and COMT genotypes gives a more complete picture of estrogen pathway efficiency than either gene alone.
ESR1 variants affect estrogen receptor alpha activity — influencing tissue sensitivity to circulating estrogen, bone mineral density response, and the efficacy of hormone replacement therapy. ESR1 genotype informs both the risk context for estrogen-related conditions and the expected benefit from HRT in peri- and post-menopause.
SHBG regulates the bioavailability of estrogen and testosterone by binding them in circulation. SHBG variants affect free hormone levels — influencing PCOS risk, libido, energy, and hormonal symptom severity independently of total hormone production. A critical variable in hormonal health assessment that is frequently overlooked without genetic context.
VDR variants affect vitamin D receptor function — determining the efficacy of vitamin D in maintaining bone mineral density. In the context of declining estrogen, VDR genotype determines how much supplemental vitamin D and calcium intervention is needed to maintain bone protection — directly actionable in peri- and post-menopausal protocols.
CYP17A1 is a key enzyme in androgen and estrogen biosynthesis. Variants affect the ratio of androgen to estrogen production — contributing to PCOS phenotypes, acne, and hirsutism in affected women. Part of the hormonal balance picture for reproductive and metabolic health.
A structured estrogen pathway assessment — CYP1A1, CYP1B1, and COMT genotypes combined into a meaningful hormonal metabolism profile. Directly actionable: DIM supplementation, cruciferous vegetable protocols, and lifestyle factors that shift estrogen metabolism toward protective pathways.
ESR1 and SHBG genotypes providing a sensitivity framework for hormonal symptoms — explaining why two women with identical hormone levels experience different symptom burdens and respond differently to hormonal interventions.
VDR and bone metabolism genetics informing vitamin D dosing, calcium protocol, and exercise type for bone maintenance. Most critical in peri- and post-menopause when estrogen-mediated bone protection declines — the genetics determine how much supplemental intervention compensates.
Comprehensive supplement protocol — DIM/I3C for estrogen metabolism, methylfolate for COMT support, targeted vitamin D and K2 for bone, and magnesium for hormonal symptom management — all calibrated to the specific genotype combination rather than generic women's health protocols.
Whether you're building a women's health app, a hormonal wellness product, or a longevity clinic focused on female health — let's discuss what genomic personalization looks like in your context.